ArticleScientific reports2026
Correlations of m6A methylation-related mRNAs with thyroid cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
N6-methyladenosine (m6A) RNA methylation plays a crucial role in tumorigenesis. However, the specific role of m6A modifications in the malignant progression of papillary thyroid carcinoma (PTC) without autoimmune thyroid disease (AITD) remains unclear. We analyzed a randomly selected subset of three pairs from a total cohort of 26 pairs of cancerous and para-cancerous tissues from patients with PTC without AITD to investigate global m6A levels and the gene expression of key factors driving m6A methylation. Our results revealed a significant increase in global m6A methylation in cancerous tissues, accompanied by upregulation of the m6A "reader" gene IGF2BP2. Of the 486 upregulated and 39 downregulated genes identified in cancerous tissues, most of the top-enriched pathways were associated with activated genes and contributed to cancer progression. A significant protein-protein interaction between IGF2BP2 and several key cancer-related genes, particularly FN1 and LAMB3, was observed. Moreover, 313 mRNAs, 55 lncRNAs, and 8 ncRNAs exhibited significant m6A methylation differences, overlapping with differentially expressed cancer-associated genes, particularly NUM, which was recently identified as a potential biomarker for PTC. These findings underscore the importance of m6A-related mechanisms and functions in PTC without AITD development and suggest that FN1-, NMU-, and LAMB3-associated pathways may be potential therapeutic targets and molecular mechanisms for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.